Type 1 Diabetes Mellitus and COVID-19

Article Information

Kamyar Asadipooya1, Pengli Bu2

1Kamyar Asadipooya, Assistant Professor, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Barnstable Brown Diabetes and Obesity Center, University of Kentucky, Lexington, KY, USA

2Pengli Bu, Assistant Professor, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY, USA

*Corresponding Author: Kamyar Asadipooya, MD, Assistant Professor of Medicine, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Barnstable Brown Diabetes and Obesity Center, University of Kentucky, Lexington, KY 40504, USA

Received: 29 February 2024; Accepted: 14 March 2024; Published: 29 March 2024

Citation:

Kamyar Asadipooya, Pengli Bu. Type 1 Diabetes Mellitus and COVID-19. Archives of Clinical and Medical Case Reports. 8 (2024): 69-70

View / Download Pdf Share at Facebook

Abstract

Type 1 diabetes mellitus (T1DM) accounts for around 5-10% of all diagnosed cases of diabetes. It is caused by lack of insulin production, typically secondary to autoimmune destruction of pancreatic β-cell. The exact mechanisms and etiologies are not entirely revealed, but it is thought that genes and environmental factors, such as viruses, might trigger autoimmunity against the pancreas.

Keywords

ACE2; COVID-19; DPP-4; SARS-CoV-2; T1DM

ACE2 articles; COVID-19 articles; DPP-4 articles; SARS-CoV-2 articles; T1DM articles.

ACE2 articles ACE2 Research articles ACE2 review articles ACE2 PubMed articles ACE2 PubMed Central articles ACE2 2023 articles ACE2 2024 articles ACE2 Scopus articles ACE2 impact factor journals ACE2 Scopus journals ACE2 PubMed journals ACE2 medical journals ACE2 free journals ACE2 best journals ACE2 top journals ACE2 free medical journals ACE2 famous journals ACE2 Google Scholar indexed journals COVID-19 articles COVID-19 Research articles COVID-19 review articles COVID-19 PubMed articles COVID-19 PubMed Central articles COVID-19 2023 articles COVID-19 2024 articles COVID-19 Scopus articles COVID-19 impact factor journals COVID-19 Scopus journals COVID-19 PubMed journals COVID-19 medical journals COVID-19 free journals COVID-19 best journals COVID-19 top journals COVID-19 free medical journals COVID-19 famous journals COVID-19 Google Scholar indexed journals ultrasound articles ultrasound Research articles ultrasound review articles ultrasound PubMed articles ultrasound PubMed Central articles ultrasound 2023 articles ultrasound 2024 articles ultrasound Scopus articles ultrasound impact factor journals ultrasound Scopus journals ultrasound PubMed journals ultrasound medical journals ultrasound free journals ultrasound best journals ultrasound top journals ultrasound free medical journals ultrasound famous journals ultrasound Google Scholar indexed journals DPP-4 articles DPP-4 Research articles DPP-4 review articles DPP-4 PubMed articles DPP-4 PubMed Central articles DPP-4 2023 articles DPP-4 2024 articles DPP-4 Scopus articles DPP-4 impact factor journals DPP-4 Scopus journals DPP-4 PubMed journals DPP-4 medical journals DPP-4 free journals DPP-4 best journals DPP-4 top journals DPP-4 free medical journals DPP-4 famous journals DPP-4 Google Scholar indexed journals SARS-CoV-2 articles SARS-CoV-2 Research articles SARS-CoV-2 review articles SARS-CoV-2 PubMed articles SARS-CoV-2 PubMed Central articles SARS-CoV-2 2023 articles SARS-CoV-2 2024 articles SARS-CoV-2 Scopus articles SARS-CoV-2 impact factor journals SARS-CoV-2 Scopus journals SARS-CoV-2 PubMed journals SARS-CoV-2 medical journals SARS-CoV-2 free journals SARS-CoV-2 best journals SARS-CoV-2 top journals SARS-CoV-2 free medical journals SARS-CoV-2 famous journals SARS-CoV-2 Google Scholar indexed journals treatment articles treatment Research articles treatment review articles treatment PubMed articles treatment PubMed Central articles treatment 2023 articles treatment 2024 articles treatment Scopus articles treatment impact factor journals treatment Scopus journals treatment PubMed journals treatment medical journals treatment free journals treatment best journals treatment top journals treatment free medical journals treatment famous journals treatment Google Scholar indexed journals CT articles CT Research articles CT review articles CT PubMed articles CT PubMed Central articles CT 2023 articles CT 2024 articles CT Scopus articles CT impact factor journals CT Scopus journals CT PubMed journals CT medical journals CT free journals CT best journals CT top journals CT free medical journals CT famous journals CT Google Scholar indexed journals surgery articles surgery Research articles surgery review articles surgery PubMed articles surgery PubMed Central articles surgery 2023 articles surgery 2024 articles surgery Scopus articles surgery impact factor journals surgery Scopus journals surgery PubMed journals surgery medical journals surgery free journals surgery best journals surgery top journals surgery free medical journals surgery famous journals surgery Google Scholar indexed journals syndrome articles syndrome Research articles syndrome review articles syndrome PubMed articles syndrome PubMed Central articles syndrome 2023 articles syndrome 2024 articles syndrome Scopus articles syndrome impact factor journals syndrome Scopus journals syndrome PubMed journals syndrome medical journals syndrome free journals syndrome best journals syndrome top journals syndrome free medical journals syndrome famous journals syndrome Google Scholar indexed journals T1DM articles T1DM Research articles T1DM review articles T1DM PubMed articles T1DM PubMed Central articles T1DM 2023 articles T1DM 2024 articles T1DM Scopus articles T1DM impact factor journals T1DM Scopus journals T1DM PubMed journals T1DM medical journals T1DM free journals T1DM best journals T1DM top journals T1DM free medical journals T1DM famous journals T1DM Google Scholar indexed journals

Article Details

Abbreviations:

ACE2 - Angiotensin-Converting Enzyme 2; ADAM17 - A Disintegrin and Metalloproteinase Domain-Containing Protein 17; COVID-19 - Coronavirus Disease 2019; DKA- Diabetic Ketoacidosis; DPP-4 - Dipeptidyl Peptidase-4; SARS-CoV-2 - Severe Acute Respiratory Syndrome Coronavirus 2; TMPRSS2 - Transmembrane Protease Serine 2; T1DM - Type 1 Diabetes Mellitus.

Commentary

Currently, SARS-CoV-2 infection and accompanying complications are the main concern of the world. Hyperglycemia is a typical complication of COVID-19, and there is evidence of a correlation between COVID-19 and new onset diabetes (T1DM) [1]. The association between SARS-CoV-2 infection and new onset T1DM has been reported in several systematic reviews. There are also relations between SARS-CoV-2 infection and increased incidence and severity of diabetic ketoacidosis (DKA) [2]. Evidently, the COVID-19 pandemic is associated with not only increased incidence of T1DM, but also delayed diagnosis and worsening of clinical conditions. Of note, understanding the mechanisms of developing T1DM following SARS-CoV-2 infection can help prevent this devastating complication. The proposed mechanisms of triggering T1DM following SARS-CoV-2 infection include direct damage of pancreatic β-cells, and virus-mediated immune activation, which results in local and systemic inflammatory responses and autoimmunity. The cytokine storm of SARS-CoV-2 infection, vascular damage, endothelial dysfunction, and acute pancreatitis could be additional causes for the increased incidence of new onset T1DM and DKA. In addition, treatment (such as steroids), increased insulin resistance, and prolonged viral replication in several organs such as adipose tissue can impair insulin function and cause hyperglycemia [1]. Furthermore, T1DM and even anti-GAD antibody-positive fulminant T1DM have been reported following COVID-19 vaccination [3], which may underscore the virus-mediated immune activation or autoimmunity as important mechanisms of pancreatic β-cell destruction.

The current treatments for SARS-CoV-2 infection employ mainly antiviral agents, including Paxlovid. However, there is a concern regarding the occurrence of new SARS-CoV-2 strains, which can potentially acquire resistance to the current antiviral treatments [4]. Therefore, we must prioritize the medications that can reduce SARS-CoV-2 entrance into the cells and diminish inflammatory responses. This strategy could potentially prevent the complications of COVID-19 better than antivirals that target ongoing viral replication. The receptors for SARS-CoV-2 entry into human cells are mainly angiotensin-converting enzyme 2 (ACE2) and possibly dipeptidyl peptidase 4 (DPP-4). There are cofactors such as A Disintegrin and Metalloproteinase domain-containing protein 17 (ADAM17) and host protease including transmembrane protease serine 2 (TMPRSS2) that participate in the process of SARS-CoV-2 entry into human cells. We currently have data on numerous medications that can reduce SARS-CoV-2 entry into host cells, by influencing the receptor and/or cofactors SARS-CoV-2 utilizes to enter host cells. Recent studies also reported that Ursodeoxycholic acid (UDCA), spironolactone, metformin and DPP4 inhibitors are potentially able to decrease SARS-CoV-2 entry into human cells, alleviate inflammation and improve long term outcomes [2,6]. These are relatively safe medications without much adverse side effects, which can be used in outpatients to prevent COVID-19 complications. It would be reasonable to flooring the path for future clinical trials to investigate the benefits and risks of these medications alone or in combination for treating COVID-19 patients. This may illuminate a novel path of approach in preventing or mitigating SARS-CoV-2 related complications.

Acknowledgments

Nothing

Source of funding

 There is no funding support for this project.

Conflict of interest statement

The authors declare that there are no commercial or financial relationships that could influence as a potential conflict of interest for writing the manuscript.

References

  1. Wang Y, Guo H, Wang G, et al. COVID-19 as a Trigger for type 1 diabetes. The Journal of clinical endocrinology and metabolism 108 (2023): 2176-2183.
  2. Kashfi K, Anbardar N, Asadipooya A, et al. Type 1 Diabetes and COVID-19: A Literature Review and Possible Management. Int J Endocrinol Metab 21 (2023): e139768.
  3. Izumi T, Takahashi H, Takahashi H. Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination. Diabetol Int 14 (2023): 422-426.
  4. Edwin HV, Antony CS. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon 9 (2023): e13952.
  5. Viriyakitkosol R, Wanitchang A, Srisutthisamphan K, et al. Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera. Front Immunol 14 (2023): 1219546.
  6. Davarpanah MA, Adatorwovor R, Mansoori Y, et al. Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study. J Endocrinol Invest 47 (2024): 235-243.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved